NitroMed, Inc : Premium Company Profile

Questions: Discounts, Updates etc.

Price: $495.00

Publication Date: 2007-12-17

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

NitroMed is focused on the development and commercialization of products for the treatment of diseases in the area of cardiology. The company applies Nitric Oxide (NO) technology to produce NO-based compounds. The company has only one marketed product, BiDil for the treatment of heart failure in African-American.


Scope

  • Contains corporate strategy, value chain presence and SWOT Analysis
  • Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
  • Includes information on suppliers/ partners, shareholding structure and key employees with biographies


    • Report Highlights
    NitroMed is engaged in the development and commercialization of pharmaceutical products for cardiovascular indications. The company has developed Nitric Oxide (NO) technology that provides stable and pharmaceutically elegant forms of NO to produce new NO-based compounds and extend the product lifecycle of existing medicines by adding an NO-donor.

    The company's total revenues increased at a CAGR of 86% during 2002-2006, from $1 million to $12 million. The company's major contributor to revenue growth during 2002-2006 was BiDil whose sales increased at an absolute growth of +$12 million during the period.

    NitroMed's sole contributor to sales growth out to 2010 will be the sales of BiDil. The drug is indicated for the treatment of heart failure in African-Americans. Revenues from BiDil are expected to increase at a CAGR of 63%, from $12 million in 2006 to $86 million in 2010. This represents an absolute growth of +$74 million for the same period.


    Reasons to Purchase

  • Access all the important information and analysis on the company in a single report
  • Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
  • Gain access to company's adjusted five year financial data along with key ratios and market capitalization

    • Table of Contents

    Other users found this report page using the following search terms: nitromed nmi3377 competitors bidil nitromedinccompanyprofile nitromedproducts employees products competitorsofbidil drug

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


    Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.